Zonal-centrifuged human diploid cell rabies vaccine.
In order to reduce the risk of allergic reactions, a purified human diploid cell culture rabies vaccine was developed. Pitman-Moore strain of rabies was propagated in WI-38 or MRC-5 cells. Both cell strains were found to be equally suitable for pro agation of rabies virus. The virus was purified and concentrated by continuous-flow sucrose density gradient ultracentrifugation. Virus peak fractions were diluted with a stabilized and then inactivated with BPL and freeze-dried. According to the standard NIH test for potency, the vaccine proved to be very potent and stable. The results of initial clinical applications of the vaccine will be presented.
D000917:Antibody Formation; D002478:Cells, Cultured; D002501:Centrifugation, Zonal; D002986:Clinical Trials as Topic; D004171:Diploidy; D006801:Humans; D011420:Propiolactone; D011819:Rabies Vaccines / Q000302:isolation & purification* / Q000592:standards; D011820:Rabies virus / Q000302:isolation & purification*; D014774:Virulence; D014776:Virus Cultivation / Q000379:methods
D011819:Rabies Vaccines; D011420:Propiolactone